William Haseltine plans to retire as chairman and chief executive officer of Human Genome Sciences, the company said last week. He intends to step down once a new CEO has been appointed.
Jeffrey Williams has become president and chief executive officer of HandyLab, and will also join the firm's board of directors, the Ann Arbor, Mich.-based microfluidics company said yesterday. Most recently, he was president and chief executive officer of Genomic Solutions, which he co-founded.
Donald Segal has been appointed president and chief executive officer of Helix BioPharma, effective tomorrow, the Aurora, Canada-based company said last week. He has been executive vice president of Helix since 1995. Segal replaces Jerome McElroy as president. McElroy will remain chairman of the board. Helix subsidiary Sensium Technologies has been developing a biochip.
Peter Hraber has become a research scientist, and Lei Tang a research scientist and laboratory operations manager of Exagen Diagnostics, the Albuquerque, NM-based company said last week. Haber is a computational biologist, and Tang a molecular biologist.
Kenneth Holroyd has stepped down as chief operating officer and executive vice president of Genaera "to actively pursue other business interests," the Plymouth Meeting, Pa.-based company said last week. He will remain a consultant to the company. Further, Roger Vogel has become Genaera's acting chief medical officer. He has been consulting for the company since December.
Gregory Sessler has been appointed to the board of directors of immunotherapeutics company Corixa, the Seattle-based firm said today. He is the chief financial officer of Spiration of Redmond, Wash. Prior to joining Spiration, he was CFO of Rosetta Inpharmatics. Sessler holds an MBA from the Stanford Graduate School of Business and a bachelor's degree in accounting from Syracuse University.
Microarray diagnostics startup Agendia of Amsterdam, the Netherlands, has appointed two new directors to its board: Wim van Harten, a professor at the Netherlands Cancer Institute, and Pieter van der Meer of Gilde Investment Management.
Microarray company GeneXP Biosciences of Woburn, Mass., has appointed seven members to its newly established scientific advisory board: Steven Gullans, chief scientific officer of US Genomics and associate professor of medicine at Harvard Medical School, who will chair the board; David Evans, head of drug discovery at the Translational Genomics Research Institute; Geoff Ginsburg, vice president for molecular medicine and research strategy of Millennium Pharmaceuticals; Glenn Hoke, president and chief science officer of Dyad Pharmaceutical; Joshua LaBaer, director of the Harvard Institute of Proteomics at Harvard Medical School; John Quackenbush, and investigator at The Institute for Genomic Research; and Ray Stoll, president of Stoll & Associates and former director of toxicology and safety assessment at Boehringer Ingelheim.
Tariq Rana has joined the scientific advisory boards of CytRx and its subsidiary Araios, Los Angeles-based CytRx said yesterday. He is a professor of biochemistry and molecular pharmacology at the University of Massachusetts Medical School, where he studies the mechanism of RNA interference in human cells. Rana holds a PhD in chemistry from the University of California at Davis.